Xenon Pharmaceuticals Inc. — Director's Dealing 2017

Oct 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2017-10-23

Reporting Person: GOLDBERG Y. PAUL (SVP, Clinical Development)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-23	Stock Option (Right to Buy)	$3.10	A	11000	Acquired	2027-10-22	Common Shares (11000)	Direct

Footnotes

F1: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.